Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

insidermonkey.com · 2026-09-17

Exelixis, Inc. (NASDAQ:EXEL) disclosed in a September 11 filing that the FDA had extended the review of zanzalintinib by three months, setting a new target action date of March 3, 2027.

TickrTrends take: Exelixis is experiencing a regulatory delay with its zanzalintinib candidate, which introduces uncertainty into its near-term pipeline catalysts during a period when TickrTrends considers the stock undervalued. The extended review timeline means investors should monitor whether the additional three months yields data sufficiently compelling to support approval, as the resolution of this review will be material to validating the current valuation thesis in the Healthcare sector. Valuation-focused readers should track both the regulatory decision timeline and any interim data disclosures that could clarify the probability of a successful outcome.

Read the full story at insidermonkey.com →